1. O1‐10‐01: PRECLINICAL PROFILES OF DRUG CANDIDATES PROMOTING O‐LINKED GLYCOSYLATION OF TAU FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND TAUOPATHIES. (1st July 2014) Authors: Quattropani, Anna; Beher, Dirk; Nény, Maud; Ousson, Solenne; Hantson, Jennifer; Sand, Astrid; Permanne, Bruno; Wiessner, Christoph Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 1 Page Start: P148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. O1‐12‐05: PHASE 1 STUDY IN HEALTHY VOLUNTEERS OF THE O‐GLCNACASE INHIBITOR ASN120290 AS A NOVEL THERAPY FOR PROGRESSIVE SUPRANUCLEAR PALSY AND RELATED TAUOPATHIES. (1st July 2006) Authors: Ryan, J. Michael; Quattropani, Anna; Abd-Elaziz, Khalid; den Daas, Izaak; Schneider, Manfred; Ousson, Solenne; Neny, Maud; Sand, Astrid; Hantson, Jennifer; Permanne, Bruno; Wiessner, Christoph; Beher, Dirk Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 4 Page Start: P251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. O3‐04‐04: Pharmacological intervention with the novel o‐glcnacase inhibitor ASN‐561 reduces pathological tau in transgenic mice. (1st July 2015) Authors: Permanne, Bruno; Quattropani, Anna; Hantson, Jennifer; Neny, Maud; Ousson, Solenne; Sand, Astrid; Wiessner, Christoph; Beher, Dirk Journal: Alzheimer's & dementia Issue: Volume 11(2015)Supplement 7:Part 5 Page Start: P227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗